Why the U.S. Medicine Supply Chain Is One Shortage Away from Crisis

In its latest supply chain vulnerability update, the U.S. Pharmacopeia (USP) identified 100 essential medicines that, while not all currently in shortage, face elevated risk of disruption. The concern is not immediate scarcity alone but structural fragility that weakens pharma supply chain resilience. Concentrated manufacturing, limited supplier diversity, and chokepoints in upstream production can quickly lead to supply shortages if stressed.

Image

The Illusion of Redundancy

As geopolitical pressures intensify the calls to drive local drug production, USP, a nonprofit that establishes quality standards for medicines, has sharpened its focus on a critical vulnerability: The sourcing of key starting materials that underpin modern drug production.

Here is the uncomfortable truth buried inside the USP’s latest Vulnerable Medicines List: Your supply chain may look robust on paper but be one geopolitical disruption away from collapse.

The USP's 2024–2025 report identifies 100 medicines (spanning pain management, oncology, hospital solutions, and antibacterials) as critically vulnerable to shortage. Sixty-one per cent of them were not in shortage as of January 2025. That is not reassurance. That is a countdown.

Roughly 30% of the medicines on the USP’s list are currently reported as being in shortage by the U.S. Food and Drug Administration (FDA). A significant proportion of these therapies are classified as essential by either the World Health Organization or the FDA.

The list spans critical care and long-term treatment categories alike, including hospital-administered medicines, oncology treatments, corticosteroids, and anaesthetics, alongside therapies for chronic conditions such as ADHD, diabetes, and cardiovascular disease.

For VP- and SVP-level supply chain and procurement leads, the USP report is not a compliance document. It is a strategic warning. The vulnerability is not primarily at the finished dose level; rather, it is upstream in the key starting materials (KSMs) that most manufacturers have never audited.

The question is no longer whether disruption will come. It is whether your organisation has mapped its exposure before it does.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

The Friction Points: Where the Current System Is Failing

Single-country KSM dependency is the hidden fault line

The 2025 update to the USP Vulnerable Medicines List introduces a significant analytical shift: For the first time, it extends vulnerability assessment upstream to key starting materials.

The findings are alarming. Of the 100 vulnerable drugs identified, 48 rely on at least one KSM sourced exclusively from a single country.

Combined with pre-existing data showing that 41% of KSMs used in U.S.-approved active pharmaceutical ingredients (APIs) are sourced solely from China, and a further 16% from India alone, the risk picture becomes clear: Supply chain redundancy at the API or finished dose level is largely illusory if the chemical building blocks behind them trace back to one region.

Three new medicines were added to the 2025 list specifically because of this upstream exposure: Oseltamivir (Tamiflu) capsules, famotidine injection, and metoprolol tartrate injection. None were in active shortage. All were flagged because at least one of their KSMs is produced in a single geographic region. This is precisely the kind of upstream blind spot that has historically turned manageable supply stress into full-blown shortages.

Image

Injectable drugs carry disproportionate structural risk

Injectables account for 71% of all drugs on the Vulnerable Medicines List. This reflects the inherent complexity of sterile manufacturing, which demands tighter quality controls, longer lead times, and specialised facility infrastructure.

The five most vulnerable medicines identified are all injectables: Sodium chloride injection, dextrose injection, heparin sodium injection, propofol injectable emulsion, and lidocaine hydrochloride injection. These are the backbone of hospital operations globally, not niche therapeutics.

The USP Medicine Supply Map, which underpins the vulnerability scoring methodology, estimates drug shortage likelihood over a 12-month horizon with 94% accuracy. The challenge is whether procurement and supply chain teams are using it and whether policymakers are acting on it.

The tariff variable is amplifying structural weakness

Pharmaceutical tariff pressures in 2025 introduced a new layer of complexity. While major manufacturers have announced significant U.S. manufacturing investment, largely to pre-empt tariff exposure, midsize biotechs and generics manufacturers face a different reality.

The newly formed Midsized Biotech Alliance of America has argued publicly that the current policy framework creates an unfair two-tiered system. Midsize players, which produce a substantial proportion of essential generics, simply cannot absorb the capital costs of domestic facility buildout on the timelines being demanded.

The risk is that tariff-driven reshoring accelerates concentration at the top of the market while leaving supply chains for generics even more brittle.

Moving from Reactive to Predictive as an Operational Solution

Map exposure at the KSM level, not just API and FDF

The USP report makes a point that supply chain professionals need to internalise: Full upstream visibility (trace sourcing from KSMs through to APIs and then finished dosage forms) is no longer optional for strategic risk management.

The USP Medicine Supply Map now offers a KSM add-on module that enables this end-to-end visibility. Procurement teams that continue to audit only at the finished dose- or API-level are operating with a structural blind spot that the USP has now quantified.

Introduce dynamic shortage risk scoring into procurement decisions

Static preferred supplier lists are inadequate tools for a supply environment this volatile. Organisations should be integrating AI-driven shortage risk scoring, with 4-to-12-month forecasting windows, into their procurement and inventory planning cycles.

The USP Medicine Supply Map provides this capability; the question is whether it is being embedded into operational decision-making or sitting in a quarterly risk review deck that nobody reads between sessions.

Diversify KSM sourcing as a C-suite priority

Supplier diversification at the KSM level requires cross-functional leadership: Procurement, regulatory affairs, quality, and commercial must align.

Where a single-country KSM underpins a critical medicine, alternative sourcing qualification should be treated as a capital investment in supply continuity, not a procurement department project.

Regulatory teams must be brought in early, as qualifying an alternate KSM source involves analytical comparability that can take 18 to 24 months.

View interview AI in Pharma: Hype vs. What Actually Works

AI in Pharma: Hype vs. What Actually Works

Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.

Image

The Roadmap: Five Actions for Heads of Supply Chain and Procurement

• Commission a KSM-level audit of your top 20 critical medicines using the USP Medicine Supply Map methodology within the next quarter.
• Flag all products where a KSM is sourced from a single country and initiate dual-source qualification projects with regulatory affairs.
• Integrate AI-powered shortage risk forecasting into your quarterly supply planning cycle. The 12-month predictive window is now industry-standard.
• Engage government procurement bodies and GPOs to advocate for incentive structures that reward multi-source KSM supply, not just API-level redundancy.
• Brief the board: The USP's data makes a compelling case for treating supply chain resilience as a patient-safety and business-continuity issue, not an operational cost centre.

Conclusion: Pharma Supply Chain Resilience Is Now a Board-Level Imperative

The USP’s findings make one point very clear: Pharmaceutical supply chain resilience cannot be achieved at the API- or finished-dose level alone. The true faultline sits upstream, in the sourcing of key starting materials that remain invisible in most enterprise risk frameworks.

What appears to be a diversified supply network is often a single-point-of-failure system in disguise. As geopolitical risk, tariff pressure, and manufacturing concentration converge, disruption is no longer a low-probability event. Rather, it’s an operational certainty over a long enough timeline.

Therefore, resilience must move from reactive shortage management to predictive, data-driven supply architecture, where exposure is mapped, quantified, and actively mitigated before disruption occurs.

At Pharmatica, we focus on the structural inflection points shaping pharmaceutical strategy, where supply chain risk, regulatory pressure, and commercial reality intersect. Our analysis enables pharma leaders to act before vulnerabilities become crises.

Pharmatica: Insight. Connection. Impact.